[HTML][HTML] Long COVID and its Management
HC Koc, J Xiao, W Liu, Y Li, G Chen - International Journal of …, 2022 - ncbi.nlm.nih.gov
The pandemic of COVID-19 is the biggest public health crisis in 21 st Century. Besides the
acute symptoms after infection, patients and society are also being challenged by the long …
acute symptoms after infection, patients and society are also being challenged by the long …
Diagnostic performance of different sampling approaches for SARS-CoV-2 RT-PCR testing: a systematic review and meta-analysis
NNY Tsang, HC So, KY Ng, BJ Cowling… - The Lancet Infectious …, 2021 - thelancet.com
Background The comparative performance of different clinical sampling methods for
diagnosis of SARS-CoV-2 infection by RT-PCR among populations with suspected infection …
diagnosis of SARS-CoV-2 infection by RT-PCR among populations with suspected infection …
Effects of common mutations in the SARS-CoV-2 Spike RBD and its ligand, the human ACE2 receptor on binding affinity and kinetics
(RBD) and the ACE2 cell surface protein is required for viral infection of cells. Mutations in
the RBD are present in SARS-CoV-2 variants of concern that have emerged independently …
the RBD are present in SARS-CoV-2 variants of concern that have emerged independently …
Extrapulmonary manifestations of COVID-19
A Gupta, MV Madhavan, K Sehgal, N Nair… - Nature medicine, 2020 - nature.com
Although COVID-19 is most well known for causing substantial respiratory pathology, it can
also result in several extrapulmonary manifestations. These conditions include thrombotic …
also result in several extrapulmonary manifestations. These conditions include thrombotic …
COVID-19 and the elderly: insights into pathogenesis and clinical decision-making
F Perrotta, G Corbi, G Mazzeo, M Boccia… - Aging clinical and …, 2020 - Springer
The elderly may represent a specific cluster of high-risk patients for developing COVID-19
with rapidly progressive clinical deterioration. Indeed, in older individuals …
with rapidly progressive clinical deterioration. Indeed, in older individuals …
Prevalence of comorbidities among individuals with COVID-19: A rapid review of current literature
Introduction On February 11, 2020 WHO designated the name “COVID-19” for the disease
caused by “severe acute respiratory syndrome coronavirus 2”(SARS-CoV-2), a novel virus …
caused by “severe acute respiratory syndrome coronavirus 2”(SARS-CoV-2), a novel virus …
A randomized clinical trial of the efficacy and safety of interferon β-1a in treatment of severe COVID-19
E Davoudi-Monfared, H Rahmani… - Antimicrobial agents …, 2020 - Am Soc Microbiol
To the best of our knowledge, there is no published study on the use of interferon β-1a (IFN
β-1a) in the treatment of severe COVID-19. In this randomized clinical trial, the efficacy and …
β-1a) in the treatment of severe COVID-19. In this randomized clinical trial, the efficacy and …
Postdischarge thrombosis and hemorrhage in patients with COVID-19
Abstract Coronavirus disease 2019 (COVID-19) is associated with a prothrombotic state with
a high incidence of thrombotic events during hospitalization; however, data examining rates …
a high incidence of thrombotic events during hospitalization; however, data examining rates …
Emerging evidence of a COVID-19 thrombotic syndrome has treatment implications
Reports of widespread thromboses and disseminated intravascular coagulation (DIC) in
patients with coronavirus disease 19 (COVID-19) have been rapidly increasing in number …
patients with coronavirus disease 19 (COVID-19) have been rapidly increasing in number …
[HTML][HTML] SARS-CoV-2 pandemic and research gaps: Understanding SARS-CoV-2 interaction with the ACE2 receptor and implications for therapy
The COVID-19 pandemic is an emerging threat to global public health. While our current
understanding of COVID-19 pathogenesis is limited, a better understanding will help us …
understanding of COVID-19 pathogenesis is limited, a better understanding will help us …